The next ATN event will be a symposium on reimbursement models on 17 September at the Phacilitate: Leaders Europe conference, Royal Lancaster, London.
With a growing number of patient success stories, advanced therapies are attracting attention from both journalists and investors. As we draw closer to more widespread adoption of cell and gene therapies, the question everyone is asking is how are we going to pay for these therapies?
In partnership with Phacilitate: Leaders Europe, this Advanced Therapies Network (ATN) symposium on 17 September 2019 at 15:00 will unpick and debate the complexities around developing reimbursement models for cell and gene therapies.
What will reimbursement for advanced therapies look like?
In May 2019 the US FDA granted approval for Novartis’ $2.1 million treatment of spinal muscular atrophy, making it the world’s most expensive drug to-date. Whilst in Europe the reimbursement for approved cell and gene therapy products is often limited and inconsistent.
Complicating factors include small patient populations, high clinical development and production costs, limited data on long-term efficacy and safety, and ancillary hospital fees.
However, although the area has challenges, there is plenty of motivation to reach a solution and some very clever people working on finding one.
Speakers at the event
As part of the Phacilitate conference at Royal Lancaster London, the symposium will bring together leading experts from the organisations who are working in this area, including:
Pilar Pinilla-Dominguez, Senior Scientific Adviser, NICE, National Institute for Health and Care Excellence
Tamir Singer, Head of Commercial Development, NHS England
Panos Kefalas, Head of Health Economics & Market Access, Cell & Gene Therapy Catapult
Francis Pang, Vice President of Global Market Access, Orchard Therapeutics
The speakers will discuss a range of topics including the impact on the cost of capital and company valuation, lack of long-term data for reimbursement decisions and the need for companies to restructure based on long-term payment models.
ATN is delighted to be partnering with Phacilitate on this event. All ATN members can attend the symposium for free and all Phacilitate delegates will be able to attend the ATN event.
If ATN members would like to attend the rest of the Phacilitate: Leaders Europe conference they have a 10% discount which they can access from the ATN platform.
Please note your data will be passed to Phacilitate to print your badge at the event. Your data will not be used by Phacilitate for any other purposes.